Shilpa Medicare Unveils Hybrid CDMO Model at DCAT 2025

Indian CDMO, Shilpa Medicare, has launched a 'hybrid' CDMO model at DCAT 2025. Focusing on oncology, the company will begin to offer both traditional CDMO services and ready-to-license novel formulations, allowing clients to leverage Shilpa's expertise without development risks or delays. Poised to capitalize on the outsourcing trend to India, Shilpa continues to seek full-service CDMO partners.

The following article originally appeared in Manufacturing Chemist.

Shilpa Medicare is launching its new full-service hybrid CDMO at DCAT 2025.

The newly formed CDMO will see Shilpa serve both small and large molecules customers as well as peptides – with oncology a particular therapeutic specialism.

In addition to offering comprehensive discovery, clinical and commercial outsourcing services, Shilpa's hybrid CDMO model also includes commercially ready off-the-shelf novel formulations for exclusive b2b licensing.

This dual approach enables pharmaceutical companies to leverage Shilpa’s extensive expertise in oncology without the direct risks and lengthy timelines associated with development.

Through this model, pharma companies can expedite their market entry by licencing fully developed products while still benefiting from Shilpa’s robust development and manufacturing capabilities.

Commenting on the business realignment and hybrid model, Vishnukant C. Bhutada, Managing Director of Shilpa Medicare, commented: “Our goal is to offer pharmaceutical and biotech customers multiple flexible pathways to bring commercial products to market."

"On the one hand, they can leverage our development teams, cutting-edge technologies and world-class facilities in a traditional CDMO partnership – with both our GLP-1 and biologics services in high demand at DCAT."

"On the other, we have a pipeline of fully developed products that are available for exclusive licencing, eliminating development risks for our partners. However, we remain strictly a b2b-only company, ensuring we never compete with our clients.”

Shilpa Medicare has seen rapid growth in recent years, achieving a turnover of more than $150m.

The company is well-positioned to capitalise on the increasing trend of pharmaceutical outsourcing to India, offering an extensive infrastructure with five state-of-the-art R&D centres and six manufacturing facilities.

These include two dedicated drug substance plant, three drug product plant and advanced platform technologies for high-potency compounds (OEB5), ADCs, peptides, and polymers.

The total API reactor volume exceeds 800 KL, with two separate commercial drug product lines featuring advanced formulation technologies such as liquid-lyophilisation, nano liposomes, and microfluidisation.

Keshav Bhutada, Director at Shilpa Medicare Group, added: “We are building an integrated platform company and we have a very clear expansion vision to sell global partners."

"So, we expect to sign some prominent deals at DCAT. There is a real shortage globally of full-service partners with our breadth of capabilities from discovery to commercial supply and across multiple modalities whether small molecule, biological, peptide and even GLP-1."

"Consequently, demand is growing incredibly quickly as those with large DS and DP capabilities can advance projects more quickly for partners.”

For more, please find the original story source here.